GUCY2C and neoplasm: ADCs are a rapidly evolving class of drugs; considering the existing preclinical evidence for the anti-tumor effect of targeting GCC, future development and investigation of novel anti-GCC ADCs, as single agents or in combination with existing therapy regimens, may lead to clinically effective anticancer treatments.